Johnson & Johnson (NYSE:JNJ) Stake Trimmed by Sentinel Trust Co. LBA

Sentinel Trust Co. LBA cut its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 20.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,386 shares of the company’s stock after selling 1,373 shares during the quarter. Sentinel Trust Co. LBA’s holdings in Johnson & Johnson were worth $955,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. Riversedge Advisors LLC boosted its position in Johnson & Johnson by 8.6% during the 4th quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock worth $627,000 after acquiring an additional 289 shares during the period. Harrison & Co Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $933,000. Peterson Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $6,414,000. Peterson Wealth Services acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $2,691,000. Finally, Keene & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $2,851,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of several research reports. SVB Leerink reduced their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley lifted their price target on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Citigroup reduced their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, UBS Group cut their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Down 1.6 %

Shares of JNJ stock opened at $171.79 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The stock’s 50 day simple moving average is $175.41 and its 200 day simple moving average is $174.52. The company has a market capitalization of $451.67 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.48 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.63%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insiders Place Their Bets

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.